I'd love to see them take an altruistic approach and shift the focus to countries like Africa where health projects would provide a lot more utility and have a lot less regulatory burden. Once a product is visibly working in one country it's more difficult to make cases against it elsewhere.
I've heard Bill Gates state this as one of his philanthropic goals; to fund things with a cost/benefit analysis that doesn't make sense in the developed world but does elsewhere. I've worked with people involved in HIV vaccine trials overseas and, in fact, things really don't change as much as you might think. The basic tenant "first do no harm" is ingrained at an many different ethical, institutional and legal level…
While it seems to go against "do no harm" ,in reality many low cost products can start at low quality, but with time and experience improve while still offering much lower costs. So the logic can make sense.
Not sure it works for vaccines thought.
Also i wonder: what were the benefits of the vaccine you described ? were they weighted against the slight harm ?